Please assess the completion status of the following clinical trial:

Trial Title: Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) meeting the following criteria:~  * Minimum threshold peripheral blood lymphocyte count of 5 x 10\^9/L (CLL variant) OR adenopathy \> 1 cm or palpable splenomegaly (SLL variant)~ * Immunophenotypic demonstrations of a population of B lymphocytes (as defined by CD19+) that are monoclonal (by light chain exclusion) AND have ≥ 3 of the following characteristics:~    * CD5+~   * CD23+~   * Dim surface light chain expression~   * Dim surface CD20 expression~   * FISH analysis is negative for IGH/CCND1 and/or immunostaining is negative for cyclin D1 expression~* Must have progressive disease as indicated by any of the following characteristics (based on standard criteria for treatment):~  * Symptomatic CLL characterized by any of the following:~    * Weight loss \> 10% within the past 6 months~   * Extreme fatigue~   * Fevers \> 38.5° C (not due to infection)~   * Drenching night sweats without evidence of infection~ * Evidence of progressive bone marrow failure with hemoglobin \< 11 g/dL or platelet count \< 100 x 10\^9/L~ * Massive and progressive splenomegaly (\> 6 cm below left costal margin)~ * Massive (\> 10 cm) or rapidly progressive lymphadenopathy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Creatinine ≤ 2 times upper limit of normal (ULN)~* Total bilirubin ≤ 3.0 times ULN OR direct bilirubin ≤ 1.5 times ULN~* AST ≤ 3.0 times ULN (unless due to hemolysis or CLL)~* Willing to provide mandatory blood samples for research studies~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for up to 12 months after completion of study treatment~* No other active primary malignancy that requires treatment or limits survival to ≤ 2 years~* No active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia~* No New York Heart Association class III or IV heart disease~* No myocardial infarction within the past month~* No uncontrolled infection~* No HIV infection or AIDS~* No active hepatitis B infection (i.e., HBsAg or HBeAg positivity) or hepatitis C infection by serology~* No other comorbid condition~PRIOR CONCURRENT THERAPY:~* No more than 3 prior treatment regimens for CLL that included purine analogue drugs (e.g., fludarabine, pentostatin, or cladribine) OR previously untreated CLL in patients with high-risk disease due to 17p13 deletion on FISH analysis~* More than 4 weeks since prior major surgery~* More than 2 months since prior alemtuzumab~* Prior corticosteroids allowed~* No concurrent continuous systemic corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Pentostatin, Alemtuzumab, Rituximab) (Type: EXPERIMENTAL): Course 1: Patients receive:~* 2 mg/m\^2 pentostatin IV on days 8 and 22;~* 3 mg alemtuzumab subcutaneously (SC) on day 3;~* 10 mg alemtuzumab SC on day 4;~* 30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~* 20 mg/m\^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~* 6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~* 2 mg/m\^2 pentostatin IV on days 1 and 15;~* 30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~* 20 mg/m\^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~* 6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3).

Based on this trial design, predict the completion outcome and termination type (if applicable).